AntibodiesAssay KitscDNACulture CellsDevicesEnzymesExosomesIsotypesMedium & SerumsNATtrolPanelPCRPcr KitsReagentsRia KitsTest KitsVector & Virus

Malaria during pregnancy and transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV) antibodies: a cohort study of Kenyan mother and child pairs

Background: Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in sub-Saharan African kids can vary as much as 50% by age 2 years however components affecting early age of KSHV an infection should not effectively understood. Malaria throughout being pregnant has been related to hindered transplacental switch of antibodies to a number of pathogens however whether or not it impacts transplacental switch of KSHV antibodies is unknown. We aimed to find out if in utero malaria publicity decreased the switch of KSHV antibodies throughout the placenta.
Strategies: A cohort examine in Kisumu, Kenya enrolled pregnant ladies at their first antenatal clinic (ANC) go to and adopted them via supply. We included 70 KSHV-positive, HIV-negative moms and their kids. KSHV antibody ranges have been measured by ELISA (K8.1, ORF73) and multiplex assay. Transplacental switch of antibodies was measured by the wire to maternal blood ratio (CMR) of KSHV antibodies. Malaria throughout being pregnant was outlined as detection of Plasmodium falciparum (Pf) DNA at any ANC go to or supply. Amongst ladies with malaria throughout being pregnant, we examined time of final malaria an infection previous to supply and malaria incidence fee.
Outcomes: KSHV seroprevalence (constructive for K8.1 or ORF73 by ELISA) amongst pregnant ladies was 88%. Neither malaria throughout being pregnant, malaria an infection timing, nor MIR have been related to maternal supply KSHV antibody blood ranges. Maternal supply and twine blood KSHV antibody ranges have been extremely correlated however these correlations didn’t differ by malaria throughout being pregnant. KSHV transplacental antibody switch was not related to malaria throughout being pregnant, malaria an infection timing, nor MIR.
Conclusions: Malaria throughout being pregnant doesn’t seem to have an effect on switch of KSHV antibodies throughout the placenta.

Dynamic modifications in anti-SARS-CoV-2 antibodies throughout SARS-CoV-2 an infection and restoration from COVID-19

Deciphering the dynamic modifications in antibodies in opposition to SARS-CoV-2 is important for understanding the immune response in COVID-19 sufferers. Right here we analyze the laboratory findings of 1,850 sufferers to explain the dynamic modifications of the whole antibody, spike protein (S)-, receptor-binding area (RBD)-, and nucleoprotein (N)-specific immunoglobulin M (IgM) and G (IgG) ranges throughout SARS-CoV-2 an infection and restoration. The era of S-, RBD-, and N-specific IgG happens one week later in sufferers with extreme/essential COVID-19 in comparison with sufferers with gentle/average illness, whereas S- and RBD-specific IgG ranges are 1.5-fold greater in extreme/essential sufferers throughout hospitalization. The RBD-specific IgG ranges are 4-fold greater in older sufferers than in youthful sufferers throughout hospitalization.
As well as, the S- and RBD-specific IgG ranges are 2-fold greater within the recovered sufferers who’re SARS-CoV-2 RNA damaging than those that are RNA constructive. Decrease S-, RBD-, and N-specific IgG ranges are related to a decrease lymphocyte proportion, greater neutrophil proportion, and an extended period of viral shedding. Sufferers with low antibody ranges on discharge would possibly thereby have a excessive probability of being examined constructive for SARS-CoV-2 RNA after restoration. Our examine gives necessary data for COVID-19 analysis, remedy, and vaccine growth.
Throughout the coronavirus illness 2019 (COVID-19) pandemic, many international locations skilled an infection in healthcare staff (HCW) resulting from overburdened healthcare techniques. Nevertheless, whether or not contaminated HCW purchase protecting immunity in opposition to SARS-CoV-2 is unclear. Right here, we characterised SARS-CoV-2-specific antibody responses in Norwegian HCW in a potential cohort examine.
Malaria during pregnancy and transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV) antibodies: a cohort study of Kenyan mother and child pairs
Malaria during pregnancy and transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV) antibodies: a cohort study of Kenyan mother and child pairs

A randomized, multicentre, open-label section II proof-of-concept trial investigating the medical efficacy and security of the addition of convalescent plasma to the usual of care in sufferers hospitalized with COVID-19: the Donated Antibodies Working in opposition to nCoV (DAWn-Plasma) trial

Background: The COVID-19 pandemic has imposed an infinite burden on well being care techniques all over the world. Up to now, the administration of convalescent plasma of sufferers having recovered from SARS and extreme influenza to sufferers actively having the illness confirmed promising results on mortality and appeared secure. Whether or not or not this additionally holds true for the novel SARS-CoV-2 virus is at present unknown.
Strategies: DAWn-Plasma is a multicentre nation-wide, randomized, open-label, section II proof-of-concept medical trial, evaluating the medical efficacy and security of the addition of convalescent plasma to the usual of care in sufferers hospitalized with COVID-19 in Belgium. Sufferers hospitalized with a confirmed analysis of COVID-19 are eligible when they’re symptomatic (i.e. medical or radiological indicators) and have been recognized with COVID-19 within the 72 h earlier than examine inclusion via a PCR (nasal/nasopharyngeal swab or bronchoalveolar lavage) or a chest-CT scan displaying options suitable with COVID-19 within the absence of an alternate analysis. Sufferers are randomized in a 2:1 ratio to both customary of care and convalescent plasma (energetic remedy group) or customary of care solely. The energetic remedy group receives 2 items of 200 to 250 mL of convalescent plasma inside 12 h after randomization, with a second administration of two items 24 to 36 h after ending the primary administration. The trial goals to incorporate 483 sufferers and can recruit from 25 centres throughout Belgium. The first endpoint is the proportion of sufferers that require mechanical air flow or have died at day 15. The primary secondary endpoints are medical standing on day 15 and day 30 after randomization, as outlined by the WHO Development 10-point ordinal scale, and security of the administration of convalescent plasma.

Anti-Human MIP-3 alpha Antibody

102-P67 100 µg
EUR 245.7
Description: MIP-3α is a CC chemokine that is expressed in the liver, lymph nodes, appendix, PBL and lung and can signal through the CCR6 receptor. MIP-3α is chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3α is an 8.0 kDa protein containing 70 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Anti-Human MIP-3 alpha Antibody

101-M79 500 µg
EUR 246.75
Description: MIP-3α is a CC chemokine that is expressed in the liver, lymph nodes, appendix, PBL and lung and can signal through the CCR6 receptor. MIP-3α is chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. Human MIP-3α is an 8.0 kDa protein containing 70 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

MIP-3, CCL23, human

RC315-34 5ug
EUR 125.26

Rabbit Anti Human Mip-3 Beta Polyclonal Antibody,Biotin

CPBT-65217RH 50 µg
EUR 1057.2

anti- MIP-3-beta antibody

FNab05194 100µg
EUR 606.3
Description: Antibody raised against MIP-3-beta

MIP-3 alpha, CCL20, human

RC315-31 5ug
EUR 125.26

Recombinant Human MIP-3 (CCL23)

HECCP-2301 5ug Ask for price

Recombinant Human MIP-3 (CCL23)

Z100695 20 µg
EUR 85
Description: CCL23 (MPIF-1, CK8, SCYA23), a member of the CC chemokine family, was originally isolated from a human aortic endothelial cell library and from the human monocytic cell line THP-1. It is most closely related to MIP-1 and interacts with its receptor CCR1, which is expressed on monocytes, dendritic cells, lymphocytes, and endothelial cells. Functionally, CCL23 has chemotactic activity for monocytes, DC, lymphocytes, neutrophils, osteoclast precursor cells, and endothelial cells. In contrast, CCL23 reduces the proliferation of progenitor cells giving rise to granulocyte and monocyte lineages, whereas it enhances angiogenesis of endothelial cells

Recombinant Human MIP-3 (CCL23)

Z100697 100 µg
EUR 295
Description: CCL23 (MPIF-1, CK8, SCYA23), a member of the CC chemokine family, was originally isolated from a human aortic endothelial cell library and from the human monocytic cell line THP-1. It is most closely related to MIP-1 and interacts with its receptor CCR1, which is expressed on monocytes, dendritic cells, lymphocytes, and endothelial cells. Functionally, CCL23 has chemotactic activity for monocytes, DC, lymphocytes, neutrophils, osteoclast precursor cells, and endothelial cells. In contrast, CCL23 reduces the proliferation of progenitor cells giving rise to granulocyte and monocyte lineages, whereas it enhances angiogenesis of endothelial cells

Recombinant Human MIP-3 (CCL23)

Z100699 1.0 mg
EUR 2025
Description: CCL23 (MPIF-1, CK8, SCYA23), a member of the CC chemokine family, was originally isolated from a human aortic endothelial cell library and from the human monocytic cell line THP-1. It is most closely related to MIP-1 and interacts with its receptor CCR1, which is expressed on monocytes, dendritic cells, lymphocytes, and endothelial cells. Functionally, CCL23 has chemotactic activity for monocytes, DC, lymphocytes, neutrophils, osteoclast precursor cells, and endothelial cells. In contrast, CCL23 reduces the proliferation of progenitor cells giving rise to granulocyte and monocyte lineages, whereas it enhances angiogenesis of endothelial cells

Anti-Human MIP-3 Rabbit Polyclonal Antibody

TA328391 100 µg Ask for price

MIP-3-alpha/CCL20, Human

HY-P7262 10ug
EUR 321.6

MIP-3/CCL23, human recombinant

7175-10 each
EUR 248.4

MIP-3/CCL23, human recombinant

7175-50 each
EUR 810

Goat Anti Human Mip-1 Alpha Polyclonal Antibody

CPBT-65207GH 0.1 mg
EUR 1057.2

Rabbit Anti Human Mip-1 Beta Polyclonal Antibody

CPBT-65212RH 0.1 mg
EUR 1057.2

Anti-Human MIP-4 Antibody

102-P69 100 µg
EUR 245.7
Description: MIP-4 is a CC chemokine that is expressed in lymph nodes, lungs, placenta and bone marrow. MIP-4's primary receptor is unknown. MIP-4 chemoattracts lymphocytes, and has been shown to exert activity on both CD4+ and CD8+ T cells. Human MIP-4 is a 7.8 kDa protein containing 69 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Anti-Human MIP-5 Antibody

102-P70G 100 µg
EUR 245.7
Description: MIP-5 is a CC chemokine that is expressed in the heart, skeletal muscle and adrenal gland. MIP-5 primarily signals through he CCR1 receptor, but also has been found to bind to CCR3. MIP-5 is chemotactic towards T cells and monocytes. Recombinant human MIP-5 is a 10.1 kDa protein containing 92 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines

Human MIP-3 beta ELISA Kit

GWB-SKR155 96 Tests Ask for price

Anti-Human MIP-1&alpha

GWB-BIG72E 500ug Ask for price

Human CCL19/ MIP-3 ELISA KIT

E42EH-62 96T/48T Ask for price

Recombinant Human MIP-3 beta (CCL19)

Z101945 20 µg
EUR 195
Description: CCL19 is a chemokine that belongs to the CC family of growth factors and signals through the CCR7 receptor. CCl19 has been shown to be expressed in the thymus, lymph nodes and in activated bone marrow stromal cells. When anti-inflammatory signals are released, expression of CCL19 gets down-regulated – specifically by IL-10.

Recombinant Human MIP-3 beta (CCL19)

Z101949 1.0 mg
EUR 3900
Description: CCL19 is a chemokine that belongs to the CC family of growth factors and signals through the CCR7 receptor. CCl19 has been shown to be expressed in the thymus, lymph nodes and in activated bone marrow stromal cells. When anti-inflammatory signals are released, expression of CCL19 gets down-regulated – specifically by IL-10.

anti- MIP antibody

FNab05193 100µg
EUR 658.5
Description: Antibody raised against MIP

Recombinant Human MIP-3 alpha (CCL20)

HECCP-2001 5ug Ask for price

Recombinant Human MIP-3 alpha (CCL20)

Z100705 25 µg
EUR 235
Description: Macrophage inflammatory protein (MIP)-3/CCL20, also known as liver and activation-regulated chemokine (LARC) or Exodus, is a member of the CC chemokine subfamily initially noted to be expressed in human liver, lung, appendix, and tonsillar crypts. MIP-3 is selectively chemotactic for CD34(+) bone marrow cell-derived immature DCs and CD45RO(+) memory T cells that express the cognate receptor CCR6. MIP-3 produced at sites of inflammation may chemoattract CCR6-expressing immature DCs to the subepithelial region of mucosal surfaces.

Recombinant Human MIP-3 alpha (CCL20)

Z100709 1.0 mg
EUR 3900
Description: Macrophage inflammatory protein (MIP)-3/CCL20, also known as liver and activation-regulated chemokine (LARC) or Exodus, is a member of the CC chemokine subfamily initially noted to be expressed in human liver, lung, appendix, and tonsillar crypts. MIP-3 is selectively chemotactic for CD34(+) bone marrow cell-derived immature DCs and CD45RO(+) memory T cells that express the cognate receptor CCR6. MIP-3 produced at sites of inflammation may chemoattract CCR6-expressing immature DCs to the subepithelial region of mucosal surfaces.

Human MIP-3 (CCL23) Recombinant Protein

100-075S 5 µg
EUR 92.4
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Human MIP-3 (CCL23) Recombinant Protein

100-075 20 µg
EUR 196.35
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Recombinant Human MIP-3 (CCL23) Protein

PROTP55773-1 20ug
EUR 380.4
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

anti- MIP-3α antibody

FNab09791 100µg
EUR 658.5
Description: Antibody raised against MIP-3α

MIP-3/CCL23 (CHO-expressed), Human

HY-P7259 10ug
EUR 321.6

Biotinylated Anti-Human MIP-3 Rabbit Polyclonal Antibody

TA328390 50 µg Ask for price

MIP-3

EF013760 96 Tests
EUR 826.8

MIP-3

EF013761 96 Tests
EUR 826.8

MIP-3

EF016652 96 Tests
EUR 826.8

MIP-3

EF016984 96 Tests
EUR 826.8

MIP-3

EF017888 96 Tests
EUR 826.8

MIP-3

EF010865 96 Tests
EUR 826.8

MIP-3

EF012726 96 Tests
EUR 826.8

MIP-3

ant-121 0.5mg
EUR 275
Description: Mouse Anti-Human Macrophage Inflammatory Protein-3

MIP-3

PAab09791 100 ug
EUR 463.2

Human MIP-3 Recombinant Protein Lyophilized

IHUMIP3RLY5UG each
EUR 341
Description: Human MIP-3 Recombinant Protein Lyophilized

Human MIP-3 Alpha/CCL20 ELISA Kit

EK5191 96 tests
EUR 599

Human MIP-3 alpha/CCL20 ELISA Kit

RK00207 96 Tests
EUR 280

Human MIP-3 alpha/CCL20 ELISA Kit

GWB-R8MPA6 1x96 well plate Ask for price

Anti-Human MIP-1 beta Antibody

102-P64 100 µg
EUR 245.7
Description: Both MIP-1α and MIP-1β are structurally and functionally related CC chemokines. They participate in the host response to invading bacterial, viral, parasite and fungal pathogens by regulating the trafficking and activation state of selected subgroups of inflammatory cells e.g. macrophages, lymphocytes and NK cells. While both MIP-1α and MIP-1β exert similar effects on monocytes their effect on lymphocytes differ; with MIP-1α selectively attracting CD8+ lymphocytes and MIP-1β selectively attracting CD4+ lymphocytes. Additionally, MIP-1α and MIP-1β have also been shown to be potent chemoattractants for B cells, eosinophils and dendritic cells. Both human and murine MIP-1α and MIP-1β are active on human and murine hematopoietic cells. Recombinant human MIP-1βis a 7.6 kDa protein containing 69 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines

Anti-Human MIP-1 alpha Antibody

102-P63 100 µg
EUR 245.7
Description: Both MIP-1α and MIP-1β are structurally and functionally related CC chemokines. They participate in the host response to invading bacterial, viral, parasite and fungal pathogens by regulating the trafficking and activation state of selected subgroups of inflammatory cells e.g. macrophages, lymphocytes and NK cells. While both MIP-1α and MIP-1β exert similar effects on monocytes their effect on lymphocytes differ; with MIP-1α selectively attracting CD8+ lymphocytes and MIP-1β selectively attracting CD4+ lymphocytes. Additionally, MIP-1α and MIP-1β have also been shown to be potent chemoattractants for B cells, eosinophils and dendritic cells. Both human and murine MIP-1α and MIP-1β are active on human and murine hematopoietic cells. Recombinant human MIP-1α is a 7.8 kDa protein containing 69 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Anti-Human MIP-1 alpha Antibody

101-M14 500 µg
EUR 246.75
Description: Both MIP-1α and MIP-1β are structurally and functionally related CC chemokines. They participate in the host response to invading bacterial, viral, parasite and fungal pathogens by regulating the trafficking and activation state of selected subgroups of inflammatory cells e.g. macrophages, lymphocytes and NK cells. While both MIP-1α and MIP-1β exert similar effects on monocytes their effect on lymphocytes differ; with MIP-1α selectively attracting CD8+ lymphocytes and MIP-1β selectively attracting CD4+ lymphocytes. Additionally, MIP-1α and MIP-1β have also been shown to be potent chemoattractants for B cells, eosinophils and dendritic cells. Both human and murine MIP-1α and MIP-1β are active on human and murine hematopoietic cells. Recombinant human MIP-1α is a 7.8 kDa protein containing 69 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Anti-Macrophage Inflammatory Protein-3 (MIP-3) Antibody

50174 1000ug
EUR 630

Anti-Macrophage Inflammatory Protein-3 (MIP-3) Antibody

50174-1000 1000ug
EUR 630

Anti-Macrophage Inflammatory Protein-3 (MIP-3) Antibody

50174-500 500ug
EUR 467

Human CCL19/MIP-3 β ELISA Kit

E16HE0218 96T
EUR 833.33

MIP 3

chm-358 5µg
EUR 60
Description: Recombinant Human Macrophage Inflammatory protein-3 (CCL23)

Human CCL19/MIP-3 Beta ELISA Kit

EK5194 96 tests
EUR 599

Human CCL19/MIP-3 beta ELISA Kit

LF-EK50840 1×96T
EUR 777.6

CCL19 / MIP-3 beta (Human) ELISA Kit

EK-045-68 96 wells
EUR 603.72

Mouse Monoclonal anti-human CCL-19 (MIP-3 beta)

hAP-0143 100ug
EUR 250

Mouse Monoclonal anti-human CCL-3 (MIP-1 alpha)

hAP-0154 100ug
EUR 250

Mouse Monoclonal anti-human CCL-3 (MIP-1 alpha)

hAP-0154A 100ug
EUR 250

Mouse Monoclonal anti-human CCL-3 (MIP-1 alpha)

hAP-0154B 100ug
EUR 250

Sheep Polyclonal anti-Human CCL-19 (MIP-3 beta)

hAP-5710 50ug
EUR 400

Mouse Monoclonal anti-human CCL-20 (MIP-3 alpha)

hAP-0145 100ug
EUR 250

Sheep Polyclonal anti-Human CCL-20 (MIP-3 alpha)

hAP-5706 50ug
EUR 400

Human MIP-3 beta (CCL19) Recombinant Protein

100-079 20 µg
EUR 196.35
Description: MIP-3β is a CC chemokine that is expressed in the thymus, lymph nodes and in activated bone marrow stromal cells and signals through the CCR7 receptor. MIP-3β is a chemoattractant for T and B lymphocytes and myeloid progenitor cells. Human MIP-3β is active on murine cells. Recombinant human MIP-3β is an 8.8 kDa protein containing 77 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Human MIP-3 beta (CCL19) Recombinant Protein

100-079S 5 µg
EUR 92.4
Description: MIP-3β is a CC chemokine that is expressed in the thymus, lymph nodes and in activated bone marrow stromal cells and signals through the CCR7 receptor. MIP-3β is a chemoattractant for T and B lymphocytes and myeloid progenitor cells. Human MIP-3β is active on murine cells. Recombinant human MIP-3β is an 8.8 kDa protein containing 77 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Recombinant Human MIP-3 Beta (CCL19) Protein

PROTQ99731-1 20ug
EUR 380.4
Description: MIP-3β is a CC chemokine that is expressed in the thymus, lymph nodes and in activated bone marrow stromal cells and signals through the CCR7 receptor. MIP-3β is a chemoattractant for T and B lymphocytes and myeloid progenitor cells. Human MIP-3β is active on murine cells. Recombinant human MIP-3β is an 8.8 kDa protein containing 77 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Human MIP-3B (CCL23)

90219-A 5 µg
EUR 130
Description: Recombinant MIP-3(CCL-23) is a disulfide-linked monomeric protein consisting of 100 amino acid residues and migrates as an approximately 11 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 mature chain was expressed in E. coli.

Human MIP-3B (CCL23)

90219-B 20 µg
EUR 205
Description: Recombinant MIP-3 alpha (CCL20) is a disulfide-linked monomeric protein consisting of 71 amino acid residues and migrates as an approximately 8 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 alpha mature chain was expressed in E. coli.

Human MIP-3A(CCL20)

90220-A 5 µg
EUR 130
Description: Recombinant MIP-3(CCL-23) is a disulfide-linked monomeric protein consisting of 100 amino acid residues and migrates as an approximately 11 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 mature chain was expressed in E. coli.

Human MIP-3A(CCL20)

90220-B 25 µg
EUR 205
Description: Recombinant MIP-3(CCL-23) is a disulfide-linked monomeric protein consisting of 100 amino acid residues and migrates as an approximately 11 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 mature chain was expressed in E. coli.

Human MIP-3 alpha (CCL20) Recombinant Protein

100-078 20 µg
EUR 196.35
Description: MIP-3 alpha is a CC chemokine that is expressed in the liver, lymph nodes, appendix, PBL and lung and can signal through the CCR6 receptor. MIP-3 alpha is chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 alpha is an 8.0 kDa protein containing 70 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Human MIP-3 alpha (CCL20) Recombinant Protein

100-078S 5 µg
EUR 92.4
Description: MIP-3 alpha is a CC chemokine that is expressed in the liver, lymph nodes, appendix, PBL and lung and can signal through the CCR6 receptor. MIP-3 alpha is chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 alpha is an 8.0 kDa protein containing 70 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

Recombinant Human MIP-3 Alpha (CCL20) Protein

PROTP78556-2 20ug
EUR 380.4
Description: MIP-3α is a CC chemokine that is expressed in the liver, lymph nodes, appendix, PBL and lung and can signal through the CCR6 receptor. MIP-3α is chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3α is an 8.0 kDa protein containing 70 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.

MIP-4/CCL18, Human

HY-P7265 50ug
EUR 639.6

MIP-5/CCL15, Human

HY-P7266 50ug
EUR 555.6

MIP-5, CCL15, human

RC315-26 5ug
EUR 125.26

Human MIP-3 beta Recombinant Protein Lyophilized

IHUMIP3BRLY5UG each
EUR 341
Description: Human MIP-3 beta Recombinant Protein Lyophilized

MIP-3 beta Antibody

GWB-B9BE08 0.1 mg Ask for price

MIP-3-alpha/CCL20 (CHO-expressed), Human

HY-P7260 10ug
EUR 321.6

Human MIP-3 alpha Recombinant Protein Lyophilized

IHUMIP3ARLY5UG each
EUR 341
Description: Human MIP-3 alpha Recombinant Protein Lyophilized

Human MIP-5 Antibody Pair Set

ABPR-ZB194 5 plates, 15 plates Ask for price
Description: Quantitative determination of Human MIP-5

Anti-LP mip Antibody

Y123203 100 µl
EUR 320

Anti-LP mip Antibody

Y123204 100 µl
EUR 320

MIP-3 Alpha Antibody

GWB-65BCF6 0.1 mg Ask for price

Recombinant Human CCL19/MIP-3 beta Protein

RP01634 100μg
EUR 39

MIP-3-beta Antibody

abx235194-100ug 100 ug
EUR 577.2

MIP-3-beta Antibody

abx235194-100g 100 µg
EUR 350

Anti-Human MIP-3β Rabbit Polyclonal Antibody

TA328395 100 µg Ask for price

MIP-3beta, human recombinant

4494-1000 each
EUR 6558

MIP-3beta, human recombinant

4494-20 each
EUR 379.2

MIP-1beta, human recombinant

4247-10 each
EUR 379.2

MIP-1beta, human recombinant

4247-1000 each
EUR 6558

Anti-CXCL2 / MIP-2 antibody

STJ71916 100 µg
EUR 430.8

Human MIP-1β ELISA Kit

EHM0017 96Tests
EUR 625.2

Human MIP-3α ELISA Kit

EHM0019 96Tests
EUR 625.2

Human MIP-3β ELISA Kit

EHM0020 96Tests
EUR 625.2

MIP-3 ALPHA

GWB-70396B 0.02 mg Ask for price

MIP-3alpha, human recombinant

4491-1000 each
EUR 4653.6

MIP-3alpha, human recombinant

4491-20 each
EUR 320.4

MIP-1alpha, human recombinant

4244-100 each
EUR 1038

MIP-1alpha, human recombinant

4244-1000 each
EUR 5572.8

MIP-1alpha, human recombinant

4244-20 each
EUR 379.2

Anti-Human CCL4 (MIP-1 beta) Antibody

101-M188 100 µg
EUR 399
Description: CCL4, also known as macrophage inflammatory protein 1 beta (MIP1β), is a 12 kDa β chemokine that is secreted at sites of inflammation by activated leukocytes, lymphocytes, vascular endothelial cells, and pulmonary smooth muscle cells (1, 2). CCL4 attracts a variety of immune cells to sites of microbial infection as well as to other pathologic inflammation such as allergic asthma and ischemic myocardium. A CCL4 deficiency in mice promotes the development of autoantibodies, possibly as a result of compromised regulatory T cell recruitment. CCL4 is secreted from activated monocytes as a heterodimer with CCL3/MIP1α. The first two N-terminal amino acids can be cleaved from human CCL4 by CD26/DPPIV. Both the full length and truncated forms exert biological activity through CCR5, and the truncated form additionally interacts with CCR1 and CCR2. In humans, the ability of CCL4 to bind CCR5 inhibits the cellular entry of Mtropic HIV1 which utilizes CCR5 as a coreceptor. Both forms of CCL4 block HIV1 infection of T cells by inducing the downregulation of CCR5. Mature mouse CCL4 shares 77% and 86% amino acid sequence identity with human and rat CCL4, respectively.

Anti-Human CCL4 (MIP-1 beta) Antibody

101-M189 100 µg
EUR 399
Description: CCL4, also known as macrophage inflammatory protein 1 beta (MIP1β), is a 12 kDa β chemokine that is secreted at sites of inflammation by activated leukocytes, lymphocytes, vascular endothelial cells, and pulmonary smooth muscle cells (1, 2). CCL4 attracts a variety of immune cells to sites of microbial infection as well as to other pathologic inflammation such as allergic asthma and ischemic myocardium. A CCL4 deficiency in mice promotes the development of autoantibodies, possibly as a result of compromised regulatory T cell recruitment. CCL4 is secreted from activated monocytes as a heterodimer with CCL3/MIP1α. The first two N-terminal amino acids can be cleaved from human CCL4 by CD26/DPPIV. Both the full length and truncated forms exert biological activity through CCR5, and the truncated form additionally interacts with CCR1 and CCR2. In humans, the ability of CCL4 to bind CCR5 inhibits the cellular entry of Mtropic HIV1 which utilizes CCR5 as a coreceptor. Both forms of CCL4 block HIV1 infection of T cells by inducing the downregulation of CCR5. Mature mouse CCL4 shares 77% and 86% amino acid sequence identity with human and rat CCL4, respectively.

Anti-Human CCL4 (MIP-1 beta) Antibody

101-M190 100 µg
EUR 399
Description: CCL4, also known as macrophage inflammatory protein 1 beta (MIP1β), is a 12 kDa β chemokine that is secreted at sites of inflammation by activated leukocytes, lymphocytes, vascular endothelial cells, and pulmonary smooth muscle cells (1, 2). CCL4 attracts a variety of immune cells to sites of microbial infection as well as to other pathologic inflammation such as allergic asthma and ischemic myocardium. A CCL4 deficiency in mice promotes the development of autoantibodies, possibly as a result of compromised regulatory T cell recruitment. CCL4 is secreted from activated monocytes as a heterodimer with CCL3/MIP1α. The first two N-terminal amino acids can be cleaved from human CCL4 by CD26/DPPIV. Both the full length and truncated forms exert biological activity through CCR5, and the truncated form additionally interacts with CCR1 and CCR2. In humans, the ability of CCL4 to bind CCR5 inhibits the cellular entry of Mtropic HIV1 which utilizes CCR5 as a coreceptor. Both forms of CCL4 block HIV1 infection of T cells by inducing the downregulation of CCR5. Mature mouse CCL4 shares 77% and 86% amino acid sequence identity with human and rat CCL4, respectively.

Anti-Human MIP-5 Goat Polyclonal Antibody

TA328396 100 µg Ask for price

Human Eotaxin-3 / MIP-4a (CCL26) ELISA Kit

abx575008-96tests 96 tests
EUR 801.6

Human Eotaxin-3 / MIP-4a (CCL26) ELISA Kit

abx351155-96tests 96 tests
EUR 801.6

Human Eotaxin-3 / MIP-4a (CCL26) ELISA Kit

abx252760-96tests 96 tests
EUR 764.4

Anti-Human MIP-1a Goat Polyclonal Antibody

TA328388 100 µg Ask for price

Human CCL19/MIP-3 beta PicoKine ELISA Kit

EK0456 96 wells
EUR 510
Description: For quantitative detection of human CCL19 in cell culture supernates, cell lysates, serum and plasma (heparin, EDTA).

Human MIP-2 ELISA Kit

EHM0018 96Tests
EUR 625.2

Human MIP-4 ELISA Kit

EHM0021 96Tests
EUR 625.2

Human MIP-5 ELISA Kit

EHM0022 96Tests
EUR 625.2

Human MIP-1? ELISA Kit

GWB-SKR153 96 Tests Ask for price

Anti-Human MIP-1a Rabbit Polyclonal Antibody

TA328389 100 µg Ask for price

Anti-Human MIP-3a Rabbit Polyclonal Antibody

TA328393 100 µg Ask for price

OKRC00720-96W - MIP-3 beta ELISA Kit (Human)

OKRC00720-96W 96Wells
EUR 525

Human MIP shRNA Plasmid

20-abx952903
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

Human Macrophage Inflammatory Protein 3(MIP-3) ELISA Kit

NSL0463Hu 96 wells
EUR 468

MIP ELISA KIT|Human

EF000798 96 Tests
EUR 826.8

Human MIP-1a ELISA kit

LF-EK50245 1×96T
EUR 777.6

Human MIP-3a ELISA kit

LF-EK50249 1×96T
EUR 777.6

Human Macrophage Inflammatory Protein-3?,MIP-3? ELISA kit

201-12-0086 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Human Macrophage Inflammatory Protein-3?,MIP-3? ELISA kit

201-12-0087 96 tests
EUR 528
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

OKRC00718-96W - MIP-3 alpha ELISA Kit (Human)

OKRC00718-96W 96Wells
EUR 525

OKRC00719-96W - MIP-3 alpha ELISA Kit (Human)

OKRC00719-96W 96Wells
EUR 525

Human CCL3/MIP-1αELISA KIT

E42EH-66 96T/48T Ask for price

Human CCL4/MIP-1βELISA KIT

E42EH-67 96T/48T Ask for price

Human MIP-1alpha ELISA Kit

GWB-SKR052 96 Tests Ask for price

Human MIP-3alpha ELISA Kit

GWB-SKR154 96 Tests Ask for price
Dialogue: This trial will both present assist or discourage the usage of convalescent plasma as an early intervention for the remedy of hospitalized sufferers with COVID-19 an infection.
Tara

Leave a Reply

Your email address will not be published.